A Chromatin-associated and Transcriptionally Inactive p53-Mdm2 Complex Occurs in mdm2 SNP309 Homozygous Cells*

In cancer cells, the function of the tumor suppressor protein p53 is usually blocked. Impairment of the p53 pathway results in tumor cells with endogenous overexpression of Mdm2 via a naturally occurring single nucleotide polymorphism (SNP) in the mdm2 gene at position 309. Here we report that in mdm2 SNP309 cells, inactivation of p53 results in a chromatin-associated Mdm2-p53 complex without clearance of p53 by protein degradation. Nuclear accumulation of p53 protein in mdm2 SNP309 cells results after 6 h of camptothecin, etoposide, or mitomycin C treatment, with the p53 protein phosphorylated at Ser15. Chromatin immunoprecipitation demonstrated p53 and Mdm2 bound to p53 responsive elements. Interestingly, although the p53 protein was able to bind to DNA, quantitative PCR showed compromised transcription of endogenous target genes. Additionally, exogenously introduced p53 was incapable of activating transcription from p53 responsive elements in SNP309 cells, confirming the trans-acting nature of the inhibitor. Inhibition of Mdm2 by siRNA resulted in transcriptional activation of these p53 targets. Our data suggest that overproduction of Mdm2, resulting from a naturally occurring SNP, inhibits chromatin-bound p53 from activating the transcription of its target genes.

[1]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[2]  M. Oren,et al.  The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. , 2004, Molecular cell.

[3]  Xinbin Chen,et al.  MDM2 Is a Negative Regulator of p21WAF1/CIP1, Independent of p53* , 2004, Journal of Biological Chemistry.

[4]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[5]  P. Chène,et al.  Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface. , 2004, Molecular cancer research : MCR.

[6]  D. Livingston,et al.  Polyubiquitination of p53 by a Ubiquitin Ligase Activity of p300 , 2003, Science.

[7]  J. Bargonetti,et al.  In vivo footprinting and DNA affinity chromatography for analysis of p53 DNA binding ability. , 2003, Methods in molecular biology.

[8]  M. Olivier,et al.  Differential Activation of p53 by the Various Adducts of Mitomycin C* , 2002, The Journal of Biological Chemistry.

[9]  J. Borowiec,et al.  Stress-Dependent Nucleolin Mobilization Mediated by p53-Nucleolin Complex Formation , 2002, Molecular and Cellular Biology.

[10]  L. Freedman,et al.  Reciprocal Recruitment of DRIP/Mediator and p160 Coactivator Complexes in Vivo by Estrogen Receptor* , 2002, The Journal of Biological Chemistry.

[11]  J. Manfredi,et al.  Multiple roles of the tumor suppressor p53 , 2002, Current opinion in oncology.

[12]  Shengyun Fang,et al.  Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53* , 2000, The Journal of Biological Chemistry.

[13]  D. Meek,et al.  Serine 15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2 , 1999, The EMBO journal.

[14]  A. Levine,et al.  Functions of the MDM2 oncoprotein , 1999, Cellular and Molecular Life Sciences CMLS.

[15]  J. Niland,et al.  The MDM2 gene amplification database. , 1998, Nucleic acids research.

[16]  J. Bargonetti,et al.  p53 binds to a constitutively nucleosome free region of the mdm2 gene , 1998, Oncogene.

[17]  N. Tuteja,et al.  Nucleolin: a multifunctional major nucleolar phosphoprotein. , 1998, Critical reviews in biochemistry and molecular biology.

[18]  R. Tjian,et al.  Repression of p53-mediated transcription by MDM2: a dual mechanism. , 1997, Genes & development.

[19]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[20]  Xiao-Fan Wang,et al.  Functional Analysis of the Transforming Growth Factor βResponsive Elements in the WAF1/Cip1/p21 Promoter (*) , 1995, The Journal of Biological Chemistry.

[21]  K. Kinzler,et al.  p21 is necessary for the p53-mediated G1 arrest in human cancer cells. , 1995, Cancer research.

[22]  J. Landers,et al.  Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. , 1994, Oncogene.

[23]  X. Chen,et al.  A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. , 1993, Genes & development.

[24]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[25]  A. Levine,et al.  Mapping of the p53 and mdm-2 interaction domains. , 1993, Molecular and cellular biology.

[26]  M. Oren,et al.  Sequence‐specific DNA binding by p53: identification of target sites and lack of binding to p53 ‐ MDM2 complexes. , 1993, The EMBO journal.

[27]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.

[28]  D. Lane,et al.  Regulation of the specific DNA binding function of p53 , 1992, Cell.

[29]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[30]  B. Vogelstein,et al.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. , 1990, Cancer research.

[31]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[32]  D. Ledbetter,et al.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. , 1989, Science.